OXiGENE To Present At BIO-Europe Conference On November 6th

SOUTH SAN FRANCISCO, Calif., Nov. 4, 2013 (GLOBE NEWSWIRE) -- OXiGENE, Inc. (Nasdaq:OXGN), a clinical-stage biopharmaceutical company developing novel therapeutics to treat cancer, announced that Peter Langecker, M.D., PhD., President and Chief Executive Officer, will provide a corporate overview at the 19 th annual BIO-Europe international partnering conference on November 6, 2013 at 9:45 GMT at the Messe Wien Exhibition and Congress Center, Vienna, Austria. BIO-Europe is Europe's largest partnering conference, serving the global biotechnology, pharmaceutical and finance industries, with 1,638 companies from 52 countries participating in 2012.

About OXiGENE

OXiGENE is a clinical-stage biopharmaceutical company developing novel therapeutics to treat cancer. The Company's major focus is developing vascular disrupting agents (VDAs) that selectively disrupt abnormal blood vessels associated with solid tumor progression. OXiGENE is dedicated to leveraging its intellectual property and therapeutic development expertise to bring life-extending and life-enhancing medicines to patients.

Safe Harbor Statement

This news release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Any or all of the forward-looking statements in this press release, which include the timing of advancement, outcomes, and regulatory guidance relative to our clinical programs, achievement of our business and financing objectives may turn out to be wrong. Forward-looking statements can be affected by inaccurate assumptions OXiGENE might make or by known or unknown risks and uncertainties, including, but not limited to, the inherent risks of drug development and regulatory review, and the availability of additional financing to continue development of our programs.

Additional information concerning factors that could cause actual results to materially differ from those in the forward-looking statements is contained in OXiGENE's reports to the Securities and Exchange Commission, including OXiGENE's reports on Form 10-K, 10-Q and 8-K. However, OXiGENE undertakes no obligation to publicly update forward-looking statements, whether because of new information, future events or otherwise. Please refer to our Annual Report on Form 10-K for the fiscal year ended December 31, 2012.
CONTACT: Investor and Media Contact:         ir@oxigene.com         650-635-7000

company logo

If you liked this article you might like

OXiGENE (OXGN) Stock Gains on Positive FDA Feedback for Cancer Treatment Trials

Biotech Stock Mailbag: Aethlon Medical, Oxigene, Sarepta

Oxigene Faces Challenges for Ovarian Cancer Drug Even With Encouraging Data

Biotech Stock Mailbag: Rockwell Medical, Oxigene, Prosensa, Sarepta

3 Biotech Stocks Under $10 in Breakout Territory